Literature DB >> 2824047

Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.

C P Belani1, M Eisenberger, D Van Echo, D Hiponia, J Aisner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824047

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  5 in total

1.  Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.

Authors:  T Lad; J Schor; M Mullane; R Carroll; D Chernicoff; R Blough; L Weidner
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

2.  A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer.

Authors:  R S Witte; S Lipsitz; T L Goodman; R F Asbury; G Wilding; C M Strnad; T J Smith; D G Haller
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.

Authors:  R S Witte; P Hsieh; P Elson; M M Oken; D L Trump
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 4.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

Review 5.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.